ArticleProstate cancer and prostatic diseases2022
The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction.
Article in Prostate cancer and prostatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Complication rate across the minimally invasive surgical treatments (MISTs): where do we stand? A systematic review of the literature.Prostate cancer and prostatic diseases · 2025Pooled it
- Prostatic Urethral Lift for Obstructive Median Lobes: Consistent Results Across Controlled Trial and Real-World Settings.Journal of endourology · 2023Trial
- Predictors of durability of the prostatic urethral lift (PUL) for benign prostatic hyperplasia.Prostate cancer and prostatic diseases · 2026Article
- The "swipe" technique for prostatic urethral lift: a comparative analysis of 200 patients in a prospective cohort.Prostate international · 2026Article
- Minimally invasive surgical treatments for male lower urinary tract symptoms/benign prostatic enlargement: A review on sexual function outcomes.Bladder (San Francisco, Calif.) · 2025Review
- Assessing Micturition, sexual function, and endoscopic outcomes one year after Aquablation: a single center prospective study.World journal of urology · 2024Article
- Article
- Incidence and management of BPH surgery-related urethral stricture: results from a large U.S. database.Prostate cancer and prostatic diseases · 2024Article
- Minimally invasive techniques in quest of Holy Grail of surgical management of enlarged prostates: a narrative review.World journal of urology · 2024Review
- Mobile health: a promising tool for the management of male patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Prostate cancer and prostatic diseases · 2023Review
- Benign prostatic hyperplasia surgical re-treatment after prostatic urethral lift A narrative review.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2023Review
- Ejaculation physiology and dysfunction after BPH surgery: the role of the new MISTs.Prostate cancer and prostatic diseases · 2023Review
- Biocompatibility and efficacy of prostatic urethral lift in benign prostate hyperplasia: an in vivo and in vitro study.Scientific reports · 2023Article
- Characterization of the histological response to the Butterfly Prostatic Retraction Device in patients with benign prostatic hyperplasia.World journal of urology · 2023Article
- A Scientometric Visualization Analysis for Benign Prostatic Hyperplasia from 2016 to 2022.Urologia internationalis · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenign prostatic hyperplasia (BPH) is an affliction of the aging male population that contributes to bothersome and disruptive lower urinary tract symptoms (LUTS). The UroLift® implant has been developed as a mechanical means of widening the prostatic urethra and providing relief from lower urinary tract symptoms (LUTS) through a minimally invasive procedure.
methodsIn the current study, we utilize histological results from canine tissue, resected tissue from human subjects treated with the UroLift System and post-market surveillance data collected by the manufacturer in order to elucidate the long-term biological mechanism of action of the UroLift implant.
resultsThe delivery of the implant causes tissue compression, likely resulting in focal ischemia that causes observed local atrophy and minimal-mild chronic inflammation that ultimately remodels tissue to produce a widened prostatic urethra.
conclusionsThese studies reveal the lack of impact the device has on systemic tissue, providing evidence that the UroLift System is benign and biocompatible, and offering histologic explanation for the clinically observed durability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.